share_log

10x Genomics Preliminary Q3 Revenue Of ~$151.7M, Down 1% YoY

10x Genomics Preliminary Q3 Revenue Of ~$151.7M, Down 1% YoY

10x genomics第三季度初步营业收入约为15170万美元,同比下降1%
Benzinga ·  10/09 16:06

Preliminary Select Third Quarter 2024 Results

2024年第三季度初步选择结果

  • Revenue of approximately $151.7 million for the third quarter ended September 30, 2024, representing an approximate 1% decrease from the corresponding prior year period.
  • Preliminary revenue by source for the third quarter is expected to be as follows:
    • Instruments revenue of approximately $19.1 million, representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue.
    • Consumables revenue of approximately $126.2 million, representing 10% growth over the corresponding prior year period. Consumables revenue consists of approximately $96.5 million of Chromium consumables revenue and $29.7 million of Spatial consumables revenue.
    • Services revenue of approximately $6.4 million, representing 48% growth over the corresponding prior year period.
  • Preliminary revenue by geography for the third quarter is expected to be as follows:
    • Americas revenue of approximately $87.8 million, an 11% decrease from the prior year period.
    • EMEA revenue of approximately $37.9 million, an 18% increase over the prior year period.
    • APAC revenue of approximately $26.0 million, a 15% increase over the prior year period.
  • Cash and cash equivalents of approximately $398 million as of September 30, 2024.
  • 2024年9月30日结束的第三季度营业收入约为$15170万,较去年同期大约下降1%。
  • 预计第三季度按来源划分的初步营业收入如下:
    • 仪器收入约为$1910万,较去年同期下降46%。仪器收入包括大约$760万的Chromium仪器收入和$1140万的Spatial仪器收入。
    • 耗材收入约为$12620万,较去年同期增长10%。耗材收入包括大约$9650万的Chromium耗材收入和$2970万的Spatial耗材收入。
    • 服务收入约为$640万,较去年同期增长48%。
  • 第三季度按地理位置划分的初步营业收入预计如下:
    • 美洲营业收入约为$8780万,较去年同期下降11%。
    • 欧洲、中东、非洲营业收入约为3790万美元,比上年同期增长18%。
    • 亚太地区营业收入约为2600万美元,比上年同期增长15%。
  • 截至2024年9月30日,现金及现金等价物约为39800万美元。

"Third quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes and organization to increase effectiveness represented a significant change in how we engage with customers. The transition was more disruptive than we anticipated, especially in the Americas. At the same time, our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter. Despite these near-term headwinds, we are confident in the opportunity ahead and believe the steps we are taking will enable us to reach more customers, execute consistently across the portfolio and drive the broad democratization of our technologies."

"第三季度营业收入未达到我们的预期," 10x genomics的联合创始人兼首席执行官Serge Saxonov表示。"我们之前宣布的对商业流程和组织所做的修改旨在提高效率,这代表了我们与客户互动方式上的重大变化。过渡比我们预期的更具破坏性,尤其是在美洲地区。与此同时,我们的客户继续在支出方面保持谨慎,特别是在资本购买方面,这明显影响了本季度的仪器销售。尽管面临短期风险,我们对未来机会充满信心,并相信我们正在采取的措施将使我们能够触达更多客户,跨整个产品系列实施一致,并推动我们技术的广泛普及。"

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发